Document -
Auxilium Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (publ) enter a collaboration agreement for XIAPEX® in 71 Eurasian and African countries
-Sobi Obtains Exclusive Rights for One Commercial and One Development Indication for XIAPEX-
-In Addition to Royalties, Auxilium to Receive up to $40 M in Potential Aggregate Sales Milestones-
-
License:
Media Use
The content may be downloaded by journalists, bloggers, columnists, creators of public opinion, etc. It can be used and shared in different media channels to convey, narrate, and comment on your press releases, posts, or information, provided that the content is unmodified. The author or creator shall be attributed to the extent and in the manner required by good practice (this means, for example, that photographers should be attributed).
- File format: .pdf
